I forgot to add, that even with biologics, there is still a risk of rejection, but not so with BTM. I know most here are aware of it, but just clarifying for those who may have just started looking at this.
The interesting about Novosorb is that they can adjust the formula for strength and rate of degradation - which is why it could be used as a bone void filler.
Manufacturers of current biological products do not have this kind of flexibility - you can't really do much to change the rate of degradation to improve the vascularisation and integration process... so you kinda just get what you get. Whereas with Novosorb they can make it retain its form for different time periods depending on how long is needed for it to integrate.
Ann: BTM CE mark approval, page-180
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.06 |
Change
0.000(0.00%) |
Mkt cap ! $1.422B | |||
| Open | High | Low | Value | Volume |
| $2.02 | $2.07 | $2.02 | $1.267M | 618.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4116 | $2.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.07 | 73341 | 7 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |